BIOCOM, a Korean AI healthcare startup, has secured Series A funding from NH Bank, Nice Investment Partners, and Shinhan Venture Investment.

BIOCOM maintains Korea’s largest database of metabolome data extracted from biological samples and multi-omics data, leveraging AI to deliver personalized optimal health management solutions. While the genome represents a “blueprint,” the metabolome serves as a “report card” reflecting current dietary habits and lifestyle choices, providing the most practical health indicators.
The company operates its own Digital Metabolome Research Lab equipped with advanced precision analysis instruments including LC-MSMS and GC-MSMS, completing vertical integration of data analysis. Through this infrastructure, BIOCOM uses AI to visualize complex metabolic pathways and provides consumers with intuitive health insights, establishing strong technical barriers to entry.
This technological capability has driven steep revenue growth. In 2025, BIOCOM achieved 2.2x year-over-year revenue growth on a headquarters basis while successfully turning operationally profitable (exceeding breakeven point). The company has secured both growth momentum and profitability simultaneously. Its direct-to-consumer platform now surpasses 119,000 monthly active users (MAU).
BIOCOM plans to use the funding to accelerate development of its AI agent. The “AI Behavioral Change Coaching Agent” scheduled for official launch in the first half of 2026 will provide customers with real-time lifestyle guidance based on precision metabolome analysis results. Beyond simple information delivery, the platform aims to drive tangible physical changes in customers’ daily lives through a hyper-personalized behavioral change solution.
“Through this investment, we will secure an overwhelming competitive advantage in metabolome analysis technology and lead the data-driven precision healthcare market,” said Tae-joon Jeon, CEO of BIOCOM. “With the AI agent launching next year, we will transform into a global AI healthcare company that substantially changes the lives of customers worldwide.”
MORE FROM THE POST
- Walk101 Secures Seed Funding and TIPS Selection for AI-Powered Musculoskeletal X-ray Analysis
- Vuno Secures $6.8M Strategic Investment from Smilegate Investment to Drive Global Growth
- Barreleye Secures $10M in Strategic Series A Funding to Advance Ultrasound-based AI Diagnostic Solutions
- Connecteve Lands $10.5M Series A to Scale AI-Powered Orthopedic Tech
- Biocom Raises KRW 3 Billion to Enhance Personalized Health Services
- AI
- biocom
- BioHealth
- funding
- HealthCare
- investment
- Korea
- Korean startup
- Metabolome
- Multi-Omics
- NH Bank
- Nice Investment Partners
- Series A
- Shinhan Venture Investment
Share
Most Read
- 1
- 2
- 3
- 4
- 5


Leave a Reply